In statistics and machine learning, there’s a tradeoff between precision and recall: tune a system to be more selective and you inevitably miss more true positives. Cancer clinical trials have stumbled into a similar trap. As oncology has shifted from tumor-type-centered studies to gene-directed approaches, eligibility criteria have grown exquisitely precise. Instead of enrolling patients…
Proscia adds Pictor Labs’ virtual stains; firms cite 96–100% ‘appropriate for workup’ in evaluations
Pathology labs still spend hours, and sometimes days, moving fragile tissue through reagent-intensive staining workflows that add cost, variability and waste. Virtual staining, an approach which uses AI models to transform label-free tissue images into counterparts that mimic chemical stains, aims to compress that process significantly while preserving scarce tissue and standardizing results across sites.…
Proscia launches ‘Aperture’ AI platform to accelerate clinical trial recruitment at point of diagnosis
Only 7.1% of U.S. adults with cancer enroll in treatment trials (JCO, 2024), a bottleneck that slows drug development and limits access to targeted therapies. Proscia, a Philadelphia-based digital pathology company, aims to address that dynamic with its new tool, Aperture, which uses AI to flag potential candidates right at the point of diagnosis by…
Proscia raises $50M for AI-driven pathology
Digital pathology software developer Proscia raised $50 million in new funding to accelerate the adoption of its AI-powered pathology platform. The Series C fundraising round was led by Insight Partners, with participation from AI Capital Partners, Triangle Peak Partners and several other healthcare-focused investors. The financing brings Proscia’s total capital raised to $130 million. Proscia…
How digital pathology can help drug developers address the forked road in oncology and beyond
Digital pathology is disrupting the drug development process, replacing traditional microscopy rooted in Victorian Era approaches with high-resolution images and AI-powered analysis tools. In a recent editorial webinar, industry experts Nathan Buchbinder (chief strategy officer at Proscia), Dr. John Cochran (chief medical officer and chief pathologist at Q² Solutions, an IQVIA subsidiary), and Dr. Monika…
How digital pathology can transform the value of clinical trial information
The field of pathology is gradually going digital, marking a pronounced shift from the traditional use of glass slides, a practice that dates back to the Victorian era. Digital pathology uptake reached an “exponential” pace in the wake of the pandemic, noted Dr. Monika Lamba Saini, pathologist-scientist, director of digital innovation at Q2 Solutions, an…